Global Influenza Vaccine Market Outlook, Trend and Opportunity Analysis, Competitive Insights, Actionable Segmentation & Forecast 2024

Industry : HealthcarePublished Date : March 13th, 2018
Tutorials Get 15% Discount on First Report

The Global Influenza Vaccine Market is expected to grow steadily from USD 3.13 billion in 2017 to USD 6.17 billion in 2024, at a CAGR of 10.2% from 2018 to 2024. Factors propelling the growth of influenza vaccine market are increasing awareness regarding its treatment, and growing incidence rates of infectious diseases coupled with increasing research and development activities. The years used for the assessment are as follows;

Historical year: 2014, 2015, 2016

Base year: 2017

Forecast period: 2018 – 2024

RESEARCH METHODOLOGY

The research and analysis is based on the data and information obtained from various primary and secondary sources. The data obtained is validated by interacting with the companies of the concerned domain. The steps involved in the research methodology are;

  • Obtaining historical data of the market based on news, articles, publications, annual reports, white papers, surveys, and other secondary sources
  • Interacting with key opinion leaders of the market and developing data points based on interaction with them
  • Study of past trends in the market and their year on year Impact on the market size and share
  • Analyzing the collected data points
  • Bridging the data points to calculate the total influenza vaccine market and its various segments
  • Anticipating potential risks
  • Analyzing market forces such as drivers, restraints, and opportunities to assess new growth areas for the global influenza vaccine market
  • Finalizing the overall size and share of the global influenza vaccine market

OBJECTIVES:

  • To analyze market trends, opportunities, drivers, and restraints associated with the influenza vaccine market
  • To study market response with respect to the mergers and acquisitions in the industry
  • To profile key companies operating in the influenza vaccine market and provide their competitive landscape 

MARKET SCOPE

The research scope for Influenza Vaccine Market is as follows:

By Age Group

  • Pediatrics
  • Adults

By Influenza Viruses

  • Influenza Viruses A
  • Influenza Viruses B
  • Influenza Viruses C
  • Influenza Viruses D

By Vaccines Types

  • Quadrivalent
  • Trivalent
  • Fluzone/Vaxigrip
  • FluMist
  • FluLaval
  • Anflu
  • Fluvirin
  • Fluarix
  • Other

By Route of Drug Administration

  • Intradermal
  • Intramuscular
  • Intranasal
  • Intravenous

By End-User

  • Research Centers
  • Hospitals and Clinics

By Region

  • North America
  • Latin America
  • Europe
  • Asia-Pacific
  • Middle East and Africa

The Global Influenza Vaccine Market is expected to grow significantly from USD 3.13 billion in 2017 to USD 6.17 billion in 2024, at a CAGR of 10.2% from 2018 to 2024. Factors propelling the growth of the influenza vaccine market include increasing awareness regarding its treatment, and growing incidence rates of infectious diseases coupled with increasing research and development activities. Moreover, introduction of specialized quadrivalent influenza vaccines, and rise in the elderly population across the globe is  further boosting the growth of the market. On the other hand, string government regulation may hinder the growth of the market.

Influenza is a respiratory illness disease caused by influenza viruses that sometimes can lead to hospitalization and death in severe cases. Influenza virus affects millions of people every year, and thousands of people are hospitalized and in some cases the flu may cause death. The influenza vaccine cause antibodies after the vaccination and these antibodies provide protection against infection and inhibit the growth of the virus.

Based on the Age Group, the pediatrics segment held the major share of the global influenza vaccine market due to children especially those younger than 5 years, are at high risk for serious flu-related complications. On the basis of Vaccines Types, the quadrivalent segment holds the major share of the global influenza vaccine market owing to treatment of different type of flu viruses; influenza viruses A, and influenza viruses B, coupled with quadrivalent nasal spray vaccine approved for people 2 through 49 years of age.

North America holds the major share of global Influenza vaccine market owing to major pharmaceutical companies are currently funding clinical trials for universal flu vaccines, and growing number of patients coupled with the government initiative to promote the influenza vaccination campaigns. Europe is the second largest market share of the global Influenza vaccine market due to government approval for the new vaccine, and an increase in the size of the elderly population.

Some of the major key players in the global influenza vaccine market are GlaxoSmithKline, Merck, Protein Sciences Corporaton, Sanofi Pasteur, Inc., Pfizer, CSL Limited, MedImmune, LLC, ID Biomedical Corporation, Hualun Biologicals, Novartis, and Sinovac Biotech among others.

TABLE OF CONTENTS

CHAPTER 1. Market Scope and Methodology

1.1. Market Definition

1.2. Market Segmentation

1.2.1. Market Breakdown By, Age Group

1.2.2. Market Breakdown By, Influenza Viruses

1.2.3. Market Breakdown By, Vaccines Types

1.2.4. Market Breakdown By, Route of Drug Administration

1.2.5. Market Breakdown By, End-User

1.2.6. Market Breakdown By, Region

1.3. Research Methodology

1.3.1. Initial Data Search

1.3.2. Secondary Research

1.3.3. Primary Research

1.3.4. Scope and Assumptions

1.4. Sources

1.5. Executive Summary

CHAPTER 2. Market Outlook

2.1. Introduction

2.2. Market Outlook

2.2.1. Opportunities

2.2.1.1. Ongoing new clinical trials

2.2.1.2. Development of universal flu vaccine

2.2.2. Trends

2.2.2.1. Increasing investment by major key player for the development of influenza vaccine

2.2.2.2. Growing awareness among people

2.2.2.3. Increasing research and development activities

2.2.3. Growth Drivers

2.2.3.1. Involvement of government and non-government organizations

2.2.3.2. Growing incidence rates of infectious diseases

2.2.4. Impact Analysis of Drivers on Future Forecast of the Market

2.2.5. Restraints of the Market

2.2.5.1. Stringent government regulation

2.2.6. Impact Analysis of Restraints on Future Forecast of the Market

CHAPTER 3. Market Entry Strategy (2014-2024)

3.1. Value Chain Analysis

3.2. Competitive Analysis

3.2.1. Company Market Share Analysis

3.2.2. Porter’s Five Forces Analysis

CHAPTER 4. Global Influenza Vaccine Market Size and Forecast (2014 – 2024)

4.1. Global Influenza Vaccine Market, By Age Group

4.1.1. Pediatrics

4.1.2. Adults

4.2. Global Influenza Vaccine Market, By Influenza Viruses

4.2.1. Influenza Viruses A

4.2.2. Influenza Viruses B

4.2.3. Influenza Viruses C

4.2.4. Influenza Viruses D

4.3. Global Influenza Vaccine Market, By Vaccines Types

4.3.1. Quadrivalent

4.3.2. Trivalent

4.3.3. Fluzone/Vaxigrip

4.3.4. FluMist

4.3.5. FluLaval

4.3.6. Anflu

4.3.7. Fluvirin

4.3.8. Fluarix

4.3.9. Other

4.4. Global Influenza Vaccine Market, By Route of Drug Administration

4.4.1. Intradermal

4.4.2. Intramuscular

4.4.3. Intranasal

4.4.4. Intravenous

4.5. Global Influenza Vaccine Market, By End-User

4.5.1. Research Centers

4.5.2. Hospitals and Clinics

4.6. Global Influenza Vaccine Market, By Region

4.6.1. North America

4.6.2. Latin America

4.6.3. Europe

4.6.4. Asia-Pacific

4.6.5. Middle East and Africa

CHAPTER 5. Global Influenza Vaccine Market, By Geography (2014-2024)

5.1. North America Influenza Vaccine Market

5.1.1. North America Influenza Vaccine Market, By Age Group (USD Billion)

5.1.2. North America Influenza Vaccine Market, By Influenza Viruses (USD Billion)

5.1.3. North America Influenza Vaccine Market, By Vaccines Types (USD Billion)

5.1.4. North America Influenza Vaccine Market, By Route of Drug Administration (USD Billion)

5.1.5. North America Influenza Vaccine Market, By End-User (USD Billion)

5.1.6. North America Influenza Vaccine Market, By Country

  5.1.6.1. The U.S.

  5.1.6.2. Canada

  5.1.6.3. Mexico

  5.1.6.4. Rest of North America

5.1.6.4.1. Rest of North America Influenza Vaccine Market, By Age Group (USD Billion)

5.1.6.4.2. Rest of North America Influenza Vaccine Market, By Influenza Viruses (USD Billion)

5.1.6.4.3. Rest of North America Influenza Vaccine Market, By Vaccines Types (USD Billion)

5.1.6.4.4. Rest of North America Influenza Vaccine Market, By Route of Drug Administration (USD Billion)

5.1.6.4.5. Rest of North America Influenza Vaccine Market, By End-User (USD Billion)

5.2. Latin America Influenza Vaccine Market

5.2.1. Latin America Influenza Vaccine Market, By Age Group (USD Billion)

5.2.2. Latin America Influenza Vaccine Market, By Influenza Viruses (USD Billion)

5.2.3. Latin America Influenza Vaccine Market, By Vaccines Types (USD Billion)

5.2.4. Latin America Influenza Vaccine Market, By Route of Drug Administration (USD Billion)

5.2.5. Latin America Influenza Vaccine Market, By End-User (USD Billion)

5.2.6. Latin America Influenza Vaccine Market By Country

  5.2.6.1. Argentina

  5.2.6.2. Brazil

  5.2.6.3. Colombia

  5.2.6.4. Rest of Latin America

5.2.6.4.1. Rest of Latin America Influenza Vaccine Market, By Age Group (USD Billion)

5.2.6.4.2. Rest of Latin America Influenza Vaccine Market, By Influenza Viruses (USD Billion)

5.2.6.4.3. Rest of Latin America Influenza Vaccine Market, By Vaccines Types (USD Billion)

5.2.6.4.4. Rest of Latin America Influenza Vaccine Market, By Route of Drug Administration (USD Billion)

5.2.6.4.5. Rest of Latin America Influenza Vaccine Market, By End-User (USD Billion)

5.3. Europe Influenza Vaccine Market

5.3.1. Europe Influenza Vaccine Market, By Age Group (USD Billion)

5.3.2. Europe Influenza Vaccine Market, By Influenza Viruses (USD Billion)

5.3.3. Europe Influenza Vaccine Market, By Vaccines Types (USD Billion)

5.3.4. Europe Influenza Vaccine Market, By Route of Drug Administration (USD Billion)

5.3.5. Europe Influenza Vaccine Market, By End-User (USD Billion)

5.3.6. Europe Influenza Vaccine Market, By Country

  5.3.6.1. Germany

  5.3.6.2. France

  5.3.6.3. The U.K.

  5.3.6.4. Italy

  5.3.6.5. Spain

  5.3.6.6. France

  5.3.6.7. Monaco

  5.3.6.8. Estonia

  5.3.6.9. Rest of Europe

5.3.6.9.1. Rest of Europe Influenza Vaccine Market, By Age Group (USD Billion)

5.3.6.9.2. Rest of Europe Influenza Vaccine Market, By Influenza Viruses (USD Billion)

5.3.6.9.3. Rest of Europe Influenza Vaccine Market, By Vaccines Types (USD Billion)

5.3.6.9.4. Rest of Europe Influenza Vaccine Market, By Route of Drug Administration (USD Billion)

5.3.6.9.5. Rest of Europe Influenza Vaccine Market, By End-User (USD Billion)

5.4. Asia-Pacific Influenza Vaccine Market

5.4.1. Asia-Pacific Influenza Vaccine Market, By Age Group (USD Billion)

5.4.2. Asia-Pacific Influenza Vaccine Market, By Influenza Viruses (USD Billion)

5.4.3. Asia-Pacific Influenza Vaccine Market, By Vaccines Types (USD Billion)

5.4.4. Asia-Pacific Influenza Vaccine Market, By Route of Drug Administration (USD Billion)

5.4.5. Asia-Pacific Influenza Vaccine Market, By End-User (USD Billion)

5.4.6. Asia-Pacific Influenza Vaccine Market, By Country

  5.4.6.1. China

  5.4.6.2. Japan

  5.4.6.3. Singapore

  5.4.6.4. Australia

  5.4.6.5. India

  5.4.6.6. South Korea

  5.4.6.7. New Zealand

  5.4.6.8. Rest of Asia-Pacific

5.4.6.8.1. Rest of Asia-Pacific Influenza Vaccine Market, By Age Group (USD Billion)

5.4.6.8.2. Rest of Asia-Pacific Influenza Vaccine Market, By Influenza Viruses (USD Billion)

5.4.6.8.3. Rest of Asia-Pacific Influenza Vaccine Market, By Vaccines Types (USD Billion)

5.4.6.8.4. Rest of Asia-Pacific Influenza Vaccine Market, By Route of Drug Administration (USD Billion)

5.4.6.8.5. Rest of Asia-Pacific Influenza Vaccine Market, By End-User (USD Billion)

5.5. Middle East and Africa Influenza Vaccine Market

5.5.1. Middle East and Africa Influenza Vaccine Market, By Age Group (USD Billion)

5.5.2. Middle East and Africa Influenza Vaccine Market, By Influenza Viruses (USD Billion)

5.5.3. Middle East and Africa Influenza Vaccine Market, By Vaccines Types (USD Billion)

5.5.4. Middle East and Africa Influenza Vaccine Market, By Route of Drug Administration (USD Billion)

5.5.5. Middle East and Africa Influenza Vaccine Market, By End-User (USD Billion)

5.5.6. Middle East and Africa Influenza Vaccine Market, By Country

  5.5.6.1. Israel

  5.5.6.2. Saudi Arabia

  5.5.6.3. Ethiopia

  5.5.6.4. Iran

  5.5.6.5. Rest of Middle East and Africa

5.5.6.5.1. Rest of Middle East and Africa Influenza Vaccine Market, By Age Group (USD Billion)

5.5.6.5.2. Rest of Middle East and Africa Influenza Vaccine Market, By Influenza Viruses (USD Billion)

5.5.6.5.3. Rest of Middle East and Africa Influenza Vaccine Market, By Vaccines Types (USD Billion)

5.5.6.5.4. Rest of Middle East and Africa Influenza Vaccine Market, By Route of Drug Administration (USD Billion)

5.5.6.5.5. Rest of Middle East and Africa Influenza Vaccine Market, By End-User (USD Billion)

CHAPTER 6. Key Players and Strategic Developments (2014-2024)

6.1. GlaxoSmithKline

6.1.1. Business Overview

6.1.2. Product and Service Offering

6.1.3. Financial Overview

6.1.4. SWOT Analysis

6.1.5. Strategic Developments

6.2. Merck

6.2.1. Business Overview

6.2.2. Product and Service Offering

6.2.3. Financial Overview

6.2.4. SWOT Analysis

6.2.5. Strategic Developments

6.3. Pfizer

6.3.1. Business Overview

6.3.2. Product and Service Offering

6.3.3. Financial Overview

6.3.4. SWOT Analysis

6.3.5. Strategic Developments

6.4. Sanofi Pasteur, Inc.

6.4.1. Business Overview

6.4.2. Product and Service Offering

6.4.3. Financial Overview

6.4.4. SWOT Analysis

6.4.5. Strategic Developments

6.5. CSL Limited

6.5.1. Business Overview

6.5.2. Product and Service Offering

6.5.3. Financial Overview

6.5.4. SWOT Analysis

6.5.5. Strategic Developments

6.6. ID Biomedical Corporation

6.6.1. Business Overview

6.6.2. Product and Service Offering

6.6.3. Financial Overview

6.6.4. SWOT Analysis

6.6.5. Strategic Developments

6.7. Protein Sciences Corporation

6.7.1. Business Overview

6.7.2. Product and Service Offering

6.7.3. Financial Overview

6.7.4. SWOT Analysis

6.7.5. Strategic Developments

6.8. Novartis

6.8.1. Business Overview

6.8.2. Product and Service Offering

6.8.3. Financial Overview

6.8.4. SWOT Analysis

6.8.5. Strategic Developments

6.9. Sinovac Biotech

6.9.1. Business Overview

6.9.2. Product and Service Offering

6.9.3. Financial Overview

6.9.4. SWOT Analysis

6.9.5. Strategic Developments

6.10. MedImmune, LLC

6.10.1. Business Overview

6.10.2. Product and Service Offering

6.10.3. Financial Overview

6.10.4. SWOT Analysis

6.10.5. Strategic Developments

6.11. Hualun Biologicals

6.11.1. Business Overview

6.11.2. Product and Service Offering

6.11.3. Financial Overview

6.11.4. SWOT Analysis

6.11.5. Strategic Developments

6.12. Abbreviation

Global Influenza Vaccine Market Outlook, Trend and Opportunity Analysis, Competitive Insights, Actionable Segmentation Forecast 2024